LIMN - יחס חוב להיוון בספרים Liminatus Pharma

Liminatus Pharma relies on securing external financing as its commercial cash flow has not yet been established. The company's debt-to-book capitalization ratio visualizes current financial leverage, where the 4.56 level indicates the status of the parameter. The brand's prospects are based on the development of CAR-T methods for treating blood and stomach cancers, confirming the company's rigorous scientific standing in immuno-oncology.

This ratio reflects the dynamics of total liabilities to net assets, reacting in real-time to changes in capital structure. It measures the level of leverage, allowing a distinction between genuine financial stability and market volatility. For Liminatus Pharma (LIMN), this is critical, as antibody development costs are financed through the reduction of equity. The extent to which balance sheet capital is covered by debt obligations clearly demonstrates the risk of resource depletion for the startup.